Previous work has identified several ASCT2-targeting small molecule inhibitors and antibodies that block glutamine uptake and inhibit the proliferation of CRC cells (Schulte et al., 2018; Hara et al., 2020). This evidence concerns the gene SLC1A5 and colorectal carcinoma.